



HH

# 4

3736

PTO/SB/21 (08/90)

Approved for use through 10/31/02. OMB 0651-0131

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission	10 + 34 REF	Application Number	10/044,463
		Filing Date	January 10, 2002
		First Named Inventor	Davide R. GRASSETTI
		Group Art Unit	3736
		Examiner Name	To Be Assigned
		Attorney Docket No.	497872000400

**RECEIVED****ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Form PTO-1449 plus 1 copy (6 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement (3 pages)	<input type="checkbox"/> Request for Refund	2. Thirty-four (34) References
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Return Receipt Postcard
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

**SIGNATURE OF APPLICANT, ATTORNEY OR AGENT**

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Rd, Palo Alto, California 94304-1018
Signature	
Date	April 15, 2002

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 15, 2002.

  
Hazel M. Raskowitz

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



PATENT  
Docket No. 497872000400

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on April 15, 2002.

*Hazel M. Raskowitz*  
Hazel M. Raskowitz

**RECEIVED**

**APR 23 2002**

**TECHNOLOGY CENTER R3700**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Davide R. GRASSETTI and  
Camillo MORO

Serial No.: 10/044,463

Filing Date: January 10, 2002

For: METHOD OF IMMUNOMODULATION  
USING THIONE-FORMING  
DISULFIDES

Examiner: To Be Assigned

Group Art Unit: 3736

**INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \* is enclosed.
  - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of \* is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **497872000400**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 15, 2002


Respectfully submitted,

By:



Terri M. Shieh-Newton  
Registration No. 47,081

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5649  
Facsimile: (650) 494-0792



Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION</b> IN AN APPLICATION (Use several sheets if necessary)	Docket Number 497872000400	Application Number 10/044,463
	Applicant Davide R. GRASSETTI and Camillo MORO	
	Filing Date January 10, 2002	Group Art Unit 3736
	Mailing Date April 15, 2002	

**RECEIVED**

## U.S. PATENT DOCUMENTS

**APR 23 2002**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass TECHNOLOGY CENTER #3700	Filing Date If Earlier Than
	1.	08/03/1971	3,597,160	Grassetti			
	2.	10/17/1972	3,698,866	Grassetti et al.			
	3.	05/01/1979	4,152,439	Grassetti			
	4.	03/29/1983	4,378,364	Grassetti			
	5.	06/01/1999	5,908,861	Kun			
	6.	03/28/2000	6,043,256	Grassetti			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	7.	03/09/1976	985,170	Canada			
	8.	02/18/1999	WO 99/07368	WIPO			

## OTHER DOCUMENTS


(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	9.	Anderson et al. (1980). "T-cell-dependent B-cell Stimulation is H-2 Restricted and Antigen Dependent Only at the Resting B-cell Level," <i>PNAS</i> 77(3):1612-1616.
	10.	Barnes, D and G. Sato. (1980). "Methods for Growth of Cultured Cells in Serum-Free Medium," <i>Anal. Biochem.</i> 102:255-270.
	11.	Boot, J.H. (1995). "Effects of SH-blocking Compounds on the Energy Metabolism in Isolated Rat Hepatocytes," <i>Cell Structure and Function</i> 20(3):233-238.
	12.	D'Amico, J.J and T.W. Bartram. (1960). "Thiazolethiols and Their Derivatives," <i>J. Org. Chem.</i> 25:1336-1342.
	13.	Daves et al. (1964). "Pyrimidines. XIII. 2- and 6-Substituted 4-Pyrimidinecarboxylic Acids," <i>J. Heterocyclic Chem.</i> 1:130-133.
	14.	Dröge et al. (1991). "Modulation of Lymphocyte Functions and Immune Responses by Cysteine and Cysteine Derivatives," <i>Am. J. Med.</i> 91(3C):140-144.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 497872000400

Application Number 10/044,463

Applicant

Davide R. GRASSETTI and Camillo MORO

Filing Date January 10, 2002

Group Art Unit 3736

Mailing Date April 15, 2002


**RECEIVED****APR 23 2002****TECHNOLOGY CENTER R3700**

- |     |  |
|-----|--|
| 15. | Fox, H.H. and J.T. Gibas. (1958). "Nuclear Substitution Derivatives of Isonicotinic Acid," <i>J. Org. Chem.</i> 23:64-66.  |
| 16. | Grassetti D.R. and J.F. Murray. (1967). "The Effect of 2,2'-dithiodipyridine on Thiols and Oxidizable Substrates of Ehrlich Ascites Cells and of Normal Mouse Tissues," <i>Biochem. Pharmacol.</i> 16(12):2387-2393.   |
| 17. | Grassetti D.R. and J.F. Murray. (1968). "Restoration of Glycolysis and Respiration in Ehrlich Ascites Tumor Cells Inhibited by 2,2'-dithiodipyridine," <i>Biochem. Pharmacol.</i> 17(11):2281-2290.  |
| 18. | Grassetti et al. (1966). "Synthesis of Some Homologs of Fluoropyruvic Acid and Their Effect of the Carbohydrate Metabolism of Ehrlich Ascites Tumor and on Lactate Dehydrogenase," <i>J. Med. Chem.</i> 9:149-151.   |
| 19. | Grassetti et al. (1967). "The Effect of Some Disulfides and Thiols on the Carbohydrate Metabolism of Ehrlich Ascites Tumor," <i>J. Med. Chem.</i> 10:1170-1172.  |
| 20. | Grassetti et al. (1970). "The Effect of Some Heterocyclic Disulfides and Thiones on the Carbohydrate Metabolism of Ehrlich Ascites Tumor," <i>J. Med. Chem.</i> 13:273-276.  |
| 21. | Grassetti, D.R. (1970). "Effect of 6,6'-Dithiodinicotinic Acid on the Dissemination of Ehrlich Ascites Tumour," <i>Nature</i> 228(268):282-283.  |
| 22. | Grassetti, D.R. (1984). "Metastases Limited," <i>Nature</i> 308(5959):500.   |
| 23. | Grassetti, D.R. (1986). "6,6'-Dithiodinicotinic Acid Carboxypyridine Disulfide 6,6'Dithiobis-3-pyridinecarboxylic Acid," <i>Drugs of the Future</i> 11(7):559-561.   |
| 24. | Grassetti, D.R. (1986). "The Antimetastatic and Tumor Growth Retarding Effects of Sulfur Containing Analogs of Nicotinamide," <i>Cancer Letters</i> 31:187-195.  |
| 25. | Ham, R.G. and W.L. McKeehan. (1979). "Media and Growth Requirements," <i>Meth. Enz.</i> 58:44-93.  |
| 26. | Julius et al. (1982). "Dissociation of Two Signals Required for Activation of Resting B Cells," <i>PNAS</i> 79:1989-1993.  |
| 27. | Mahato et al. (1997). "Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives," <i>Pharm. Res.</i> 14(7):853-859.   |
| 28. | Möller, G. ed. (1987). "Activation Antigens and Signal Transduction in Lymphocyte Activation," <i>Immunol Rev.</i> 95:1-194. (Table of Contents Only).   |
| 29. | Purnell, M.R. and W.J.D. Whish. (1980). "Novel Inhibitors of Poly(ADP-Ribose) Synthetase," <i>Biochem. J.</i> 185:775-777.   |
| 30. | Rath, C. (1931). "Mercaptane und Sulfosäuren des Pyridins," <i>Justus Liebigs Ann. Chem.</i> 487:105-119.  |
| 31. | Sprent, J. (1978). "Restricted Helper Function of F <sub>1</sub> Hybrid T Cells Positively Selected to Heterologous Erythrocytes in Irradiated Parental Strain Mice II. Evidence for Restrictions Affecting Helper Cell Induction and T-B Collaboration, Both Mapping to the K-End of the H-2 Complex," <i>J. Exp. Med.</i> 147:1159-1174. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449  INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)	Docket Number 497872000400	Application Number 10/044,463
	Applicant  Davide R. GRASSETTI and Camillo MORO	
	Filing Date January 10, 2002	Group Art Unit 3736
	Mailing Date April 15, 2002	

**RECEIVED**  
**APR 23 2002**

TECHNOLOGY CENTER R3701

32.	Weltin et al. (1995). "Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly(ADP Ribose)Polymerase Inhibitor," <i>Int. J. Immunopharmac.</i> 17(4):265-271.
33.	Willoughby, D.A. and C. Wood. eds. (1977). "The History and Development of Levamisole," <i>Forum on Immunotherapy</i> 1(1):3-10.
34.	Zackheim, H.S. (1985). "Topical 6-Aminonicotinamide," Chapter 30 in <u>Psoriasis</u> . Roenick, H.H and H.I. Maibach eds. Marcell Dekker, N.Y. pp. 361-372.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	